A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth

Kara M Ruicci, Jalna Meens, Ren X Sun, Giananthony Rizzo, Nicole Pinto, John Yoo, Kevin Fung, Danielle MacNeil, Joe S Mymryk, John W Barrett, Paul C Boutros, Laurie Ailles, Anthony C Nichols, Kara M Ruicci, Jalna Meens, Ren X Sun, Giananthony Rizzo, Nicole Pinto, John Yoo, Kevin Fung, Danielle MacNeil, Joe S Mymryk, John W Barrett, Paul C Boutros, Laurie Ailles, Anthony C Nichols

Abstract

Head and neck squamous cell carcinomas (HNSCCs) frequently harbor alterations in the PI3K/AKT/mTOR signaling axis, particularly in the PIK3CA gene. PI3K-targeted agents have therefore gained considerable preclinical and clinical interest as emerging therapies for HNSCC. Identification of predictive biomarkers of response would advance the clinical application of PI3K-targeted drugs for patients, in order to achieve maximal benefit. To date, studies of drug biomarkers have largely focused on screening cell lines, with much more limited in vivo testing, usually only as validation. This approach has rarely enabled accurate predictions of clinical efficacy. Recently, clinical trials of PDX models (PDX clinical trials) have been introduced as a preclinical approach to interrogate interpatient response heterogeneity. Already, PDX clinical trial responses have been demonstrated to correlate closely with patient outcomes. Here, using both an HNSCC specific, 28-cell line panel and a PDX clinical trial of 80 xenografts derived from 20 unique HNSCC tumors, we systematically examine patterns of response to PI3K inhibition in HNSCC. We find EGFR, AKT1 and CSMD1 copy number aberrations, but not PIK3CA mutations, to be associated with responsiveness to PI3K-targeted drugs. Further, we reveal PI3Kα inhibition to be almost globally tumoristatic in HNSCC xenografts regardless of PIK3CA mutational status, emphasizing its potential as a stabilizing neoadjuvant therapy for HNSCC patients.

Trial registration: ClinicalTrials.gov NCT03138070.

Keywords: PDX clinical trial; PIK3CA; head and neck squamous cell carcinoma; targeted therapy; xenograft.

© 2018 UICC.

References

    1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
    1. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent Chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582-9.
    1. Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov 2016;16:19-34.
    1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;6:567-78.
    1. Bonner JA, Harari PM, Giralt J, et al. Articles radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
    1. Lawrence MS, Sougnez C, Lichtenstein L, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-82.
    1. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1154-7.
    1. Lui VWY, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013;3:761-9.
    1. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-7.
    1. Iglesias-Bartolome R, Martin D, Gutkind JS. Exploiting the head and neck cancer Oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets. Cancer Discov 2013;3:722-5.
    1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
    1. Fritsch C, Huang A, Chatenay-Rivauday C, et al. Characterization of the novel and specific PI3K inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 2014;13:1117-29.
    1. Elkabets M, Vora S, Juric D, et al. mTORC1 inhibition is required for sensitivity to PI3K p110 inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013;5:196ra99-9.
    1. Mazumdar T, Byers LA, Ng PKS, et al. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Mol Cancer Ther 2014;13:2738-50.
    1. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived Xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014;4:998-1013.
    1. Rosfjord E, Lucas J, Li G, et al. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol 2014;91:135-43.
    1. Campbell KM, Lin T, Zolkind P, et al. Oral cavity squamous cell carcinoma Xenografts retain complex genotypes and Intertumor molecular heterogeneity. Cell Rep 2018;24:2167-78.
    1. Gao H, Korn JM, Ferretti SEP, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 2015;21:1318-25.
    1. Chen ZW, Weinreb I, Kamel-Reid S, et al. Equivocal p16 Immunostaining in squamous cell carcinoma of the head and neck: staining patterns are suggestive of HPV status. Head Neck Pathol 2012;6:422-9.
    1. Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol 2012;6:16-24.
    1. Ocana A, Vera-Badillo F, Al-Mubarak M, et al. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One 2014;9:e95219-8.
    1. Wang L, Li F, Sheng J, et al. A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles. BMC Genomics 2015;16:S6.
    1. Li H, Wawrose JS, Gooding WE, et al. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Mol Cancer Res 2014;12:571-82.
    1. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR Axis inhibitors. Mol Cancer Ther 2011;10:558-65.
    1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
    1. Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-kinase α-selective inhibition with Alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol 2018;36:1291-99.
    1. Ihle NT, Lemos R, Wipf P, et al. Mutations in the Phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009;69:143-50.
    1. Keysar SB, Astling DP, Anderson RT, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol 2013;7:776-90.
    1. Escudero-Esparza A, Bartoschek M, Gialeli C, et al. Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer. Oncotarget 2016;7:76920-33.
    1. Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3K alpha inhibition by activating the EGFR/PKC/mTOR Axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 2015;27:533-46.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren